Early Cenobamate as a Third-Line Option in Drug-Resistant Focal Epilepsy: A Paradigm Shift?
Neurology and Therapy · 2026-06 · 15 (3) · 1191-1205
DOI: 10.1007/s40120-026-00911-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurology and Therapy, online erschienen am 13.03.2026. Verfasst von Fedele Dono und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Imaging and Clinical Science, "G. d'Annunzio" University of Chieti-Pescara, Via Dei Vestini 1, 6610, Chieti, Italy. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Center of Advanced Studies and Technologies (CAST), University “G. d’Annunzio” of Chieti–Pescara..
Abstract (Originalsprache)
INTRODUCTION: Drug-resistant epilepsy (DRE) affects nearly 30% of patients with epilepsy, and the optimal sequencing of adjunctive anti-seizure medications (ASMs) remains uncertain. Comparative real-world evidence on early use of newer ASM is limited. This study explores real-world comparative effectiveness, safety and 12-month retention of cenobamate (CNB) introduced as early third-line adjunctive therapy compared with perampanel (PER) and brivaracetam (BRV) in adults with focal-onset DRE. METHODS: This multicenter observational study included 34 CNB patients and 37 matched controls treated with PER or BRV, all after failure of two prior ASMs. Primary outcome was 12-month treatment retention; secondary outcomes included responder rates (≥ 50%, ≥ 75%, 100%) and adverse events at 3, 6 and 12 months. Comparative analyses were exploratory. Univariate analyses and longitudinal generalized linear mixed-effects models (GLMMs) were used to describe outcome trajectories over time. RESULTS: CNB showed a 12-month retention rate of 94.1%. Descriptively, seizure freedom was achieved in 62.5% of CNB patients at 12 months compared with 43.7% with PER and 16.6% with BRV. Adverse events were less frequent with CNB (9.4% at 12 months) than in controls (35.3%) and were generally non-treatment-limiting. GLMMs confirmed a significant time × treatment interaction for seizure frequency, indicating a steeper reduction in CNB patients, while no significant interaction emerged for adverse events. CONCLUSIONS: In this real-world study, early third-line CNB exhibits potentially favorable effectiveness compared with other commonly used third-line ASMs, and tolerability remained acceptable. These findings support the need for larger prospective studies to better define optimal treatment sequencing in focal-onset DRE.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neuroscience, Imaging and Clinical Science, "G. d'Annunzio" University of Chieti-Pescara, Via Dei Vestini 1, 6610, Chieti, Italy.
- Epilepsy Center, Institute of Neurology, "SS Annunziata" University Hospital of Chieti, University of Chieti-Pescara, Chieti, Italy.
- Department of Neurology, Hospital of Merano (SABES-ASDAA), Merano, Italy.
- Paracelsus Medical University, Salzburg, Austria.
- Department of Translational Biomedicine and Neurosciences, University of Bari 'Aldo Moro', Bari, Italy.
- Department of Neuroscience, Imaging and Clinical Science, "G. d'Annunzio" University of Chieti-Pescara, Via Dei Vestini 1, 6610, Chieti, Italy. ssensi@uci.edu.
Förderung
- Center of Advanced Studies and Technologies (CAST), University “G. d’Annunzio” of Chieti–Pescara.
Zitieren
APA
Dono, F., Russo, M., Agosto, R., Evangelista, G., Nucera, B., Falcicchio, G., & Sensi, S. L. (2026). Early Cenobamate as a Third-Line Option in Drug-Resistant Focal Epilepsy: A Paradigm Shift?. Neurology and Therapy, 15(3), 1191-1205. https://doi.org/10.1007/s40120-026-00911-5
Vancouver
Dono F, Russo M, Agosto R, Evangelista G, Nucera B, Falcicchio G, et al. Early Cenobamate as a Third-Line Option in Drug-Resistant Focal Epilepsy: A Paradigm Shift?. Neurology and Therapy. 2026;15(3):1191-1205. doi:10.1007/s40120-026-00911-5
BibTeX
@article{Dono2026,
author = {Dono, Fedele and Russo, Mirella and Agosto, Rita and Evangelista, Giacomo and Nucera, Bruna and Falcicchio, Giovanni and Sensi, Stefano L},
title = {Early Cenobamate as a Third-Line Option in Drug-Resistant Focal Epilepsy: A Paradigm Shift?},
journal = {Neurology and Therapy},
year = {2026},
volume = {15},
number = {3},
pages = {1191--1205},
doi = {10.1007/s40120-026-00911-5}
}
EUVIMED